Emerging applications of kinetic biomarkers in preclinical and clinical drug development

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 1, 2005, Pages 115-126

  Turner, Scott M ^a   Hellerstein, Marc K ^b,c  

^a KINEMED INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug discovery and development; High throughput screening; Kinetic biomarker; Mass spectrometry; Stable isotope

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; AZACITIDINE; BIOLOGICAL MARKER; GEMCITABINE; GENISTEIN; HYDROXYUREA; NEW DRUG; PACLITAXEL; PHORBOL 13 ACETATE 12 MYRISTATE; RALOXIFENE; RIBONUCLEOTIDE REDUCTASE; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

CELL PROLIFERATION; COMPUTER MODEL; DRUG ACTIVITY; DRUG DETERMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MASS SPECTROMETRY; NONHUMAN; REPRODUCIBILITY; REVIEW; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS;

EID: 12244260776     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Innovation/stagnation: Challenge and opportunity on the critical path to new medical products: US Food and Drug Administration, Rockville, MD, USA (2004). http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html This government document reflects a careful analysis of the state of modern drug development. The FDA recognizes a central deficiency in the current path to new medical products, which they term 'drug development science'. This formal recognition may signal a willingness to use biomarkers in a more central role in drug development and approval processes.
2. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ (2003) 22(2):151-185.
3. Duyk G: Attrition and translation. Science (2003) 302(5645):603-605. Provides an analysis of the central problem in the drug pharmaceutical industry (attrition) and its cause (poor predictive power), providing a strong rationale for improving tools that predict macroscopic or clinical response.
4. Le Fanu J (Ed): The Rise and Fall of Modern Medicine. Carroll & Graf Publishers Inc, New York, NY, USA (2000).
5. Watertow JC, Gartick PJ, Millward DJ: Protein Turnover in Mammalian Tissues and in the Whole Body. North-Holland Publishing Co, Amsterdam, the Netherlands (1978):301-325.
6. Schoenheimer R: The Dynamic State of Body Constituents. Hafner Publishers Co, New York, NY, USA (1964).
7. Wolfe RR: Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis. Wiley-Liss, New York, NY, USA (1992). Review of the in vivo application of isotopes, including analytical protocols.
8. Hellerstein MK, Murphy E: Stable isotope-mass spectrometric measurements of molecular fluxes in vivo: Emerging applications in drug development. Curr Opin Mol Ther (2004) 6(3):249-264.
9. Hellerstein MK: New stable isotope-mass spectrometric techniques for measuring fluxes through intact metabolic pathways in mammalian systems: Introduction of moving pictures into functional genomics and biochemical phenotyping. Metab Eng (2004) 6(1):85-100. Review of kinetic biomarkers for contemporary biological questions.
10. Dufner D, Previs SF: Measuring in vivo metabolism using heavy water. Curr Opin Clin Nutr Metab Care (2003) 6(5):511-517.
11. McCabe BJ, Previs SF: Using isotope tracers to study metabolism: Application in mouse models. Metab Eng (2004) 6(1):25-35. Review of physiological applications of stable isotopes with emphasis on the measurement of the turnover of carbohydrate, fat and protein in mouse models.
12. Fanara P, Turner S, Busch R, Killion S, Awada M, Turner H, Mahsut A, LaPrade KL, Stark JM, Hellerstein MK: In vivo measurement of microtubule dynamics using stable isotope labeling with heavy water: Effect of taxanes. J Biol Chem (2004) 279(48):49940-49947. Tne dynamics of microtubules provide insight into the actions of taxanes.
13. Momparler RL, Bovenzi V: DNA methylation and cancer. J Cell Physiol (2000) 183(2):145-154.
14. Davis SR, Stacpoole PW, Williamson J, Kick LS, Quinlivan EP, Coats BS, Shane B, Bailey LB, Gregory JF 3rd: Tracer-derived total and folate-dependent homocystelne remethylation and synthesis rates in humans indicate that serine is the main one-carbon donor. Am J Physiol Endocrinol Metab (2004) 286(2):E272-E279.
15. Cory JQ: Ribonucleotide reductase as a chemotherapeutic target. Adv Enzyme Regul (1988) 27:437-455.
16. Awada M, Turner S, Xiu M, Hellerstein MK: An in vivo measure of ribonucleotide reductase (RR) vs deoxyribonucleoside (dN) salvage pathway activity concurrently using stable isotopes. Proc Am Assoc Cancer Res (2004) 45:Abs 5377.
17. Boros LG, Cascante M, Lee WN: Metabolic profiling of cell growth and death in cancer: Applications in drug discovery. Drug Disc Today (2002) 7(6):364-372. Discusses novel isotopic techniques for characterizing the proliferation state of cells and their response to therapeutic agents.
18. Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, Lim S, Bassilian S, Ahmed S, Lee WN, Boros LG: Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem (2001) 276(41):37747-37753.
19. Goodson WH 3rd, Moore DH 2nd, Ljung BM, Chew K, Florendo C, Mayall B, Smith HS, Waldman FM: The functional relationship between in vivo bromodeoxyuridine labeling index and Ki-67 proliferation index in human breast cancer. Breast Cancer Res Treat (1998) 49(2):155-164.
20. Preston-Martin S, Pike MC, Ross RK, Henderson BE: Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Prog Clin Biol Res (1991) 369:21-34.
21. 2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci USA (2002) 99(24):15345-15350.
22. 2O labeling and percutaneous biopsies. Variability due to several causes is demonstrated.
23. 2O labeling: A sensitive marker of epidermal proliferation state. J Invest Dermatol (2004) 123(3):530-536. The dynamics of skin epithelial cells (keratinocytes) provide novel information about the actions of antimitotic agents and carcinogens, as well as physiological interventions (caloric restriction).
24. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C et al: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (2003) 301(5634):805-809.
25. Henn FA, Vollmayr B: Neurogenesis and depression: Etiology or epiphenomenon? Biol Psychiatry (2004) 56(3):146-150.
26. Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA: Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. Proc Natl Acad Sci USA (2004) 101(36):13363-13367.
27. Halim ND, Weickert CS, McClintock BW, Weinberger DR, Lipska BK: Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology (2004) 29(6):1063-1069.
28. Shankaran R, Schow P, King C, Stark J, Turner S, Hellerstein M: A sensitive method for measuring in vivo cell proliferation in the hippocampus of adult rats. Abstr Soc Neuroscience (2004) 34:Abs 353.19.
29. 2O labeling. The accelerated turnover of visceral TG (long hypothesized but difficult to prove) is demonstrated in rodents.
30. 2O labeling.
31. Shi Y, Bum P: Lipid metabolic enzymes: Emerging drug targets for the treatment of obesity. Nat Rev Drug Disc (2004) 3(8):695-710.
32. 2O.
33. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 37(12):1595-1607.
34. 13C]glucose breath test to the hyperinsulinemic-euglycemic clamp when determining insulin resistance. Diabetes Care (2004) 27(2):441-447.
35. 2H-OGTT). American Diabetes Association 64th Annual Scientific Sessions, Orlando, FL, USA (2004):Abs 664-P.
36. 2-abundance in breath samples with a new isotope selective-nondispersive infrared spectrometer. Z Gastroenterol (1994) 32(12):675-678.
37. 12C for carbon dioxide in human breath. Anal Chem (2002) 74(9):2003-2007.